Integrating Developments in the Treatment of Metastatic Triple-Negative Breast Cancer: The Role of the Oncology Team - Pharmacists

Integrating Developments in the Treatment of Metastatic Triple-Negative Breast Cancer: The Role of the Oncology Team

Faculty Presenter

Danielle Roman, PharmD, BCOP
Manager, Clinical Pharmacy Services
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania
 
Program Description
Triple-negative breast cancer (TNBC) is considered more aggressive and has a poorer prognosis than other subtypes of breast cancer. The heterogenicity of TNBC and lack of specific molecular targets make it challenging to treat. While TNBC is responsive to cytotoxic chemotherapy, duration of response is short, and relapses are common. Chemotherapy is the foundation of treatment for TNBC, but immune checkpoint inhibitors given in combination with chemotherapy as well as oral PARP inhibitors have expanded treatment options for TNBC based on tumor biomarkers and mutations. The rapidly growing treatment armamentarium in TNBC requires a proactive shift in the roles and responsibilities for all members of the oncology care team. Individuals involved in the care of patients with TNBC must collaborate and share best practices for management and coordination of care in order to optimize patient outcomes.

Target audience: Oncology pharmacists, pharmacy technicians, physicians, nurses
Type of activity: Application for pharmacists, physicians, and nurses; Knowledge for technicians
Release date: May 12, 2021
Expiration date: May 12, 2022
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives for Pharmacists
At the completion of this activity, participants will be able to:

• Assess the current treatment algorithms and recommendations for triple-negative breast cancer (TNBC)
• Evaluate the clinical and safety data on emerging therapies and treatment strategies for TNBC
• Examine the role of the multidisciplinary oncology team in the management of TNBC therapy including proactive monitoring and coordination of care for patients

Educational Objectives for Pharmacy Technicians
At the completion of this activity, participants will be able to:

• Articulate the current treatment recommendations for triple-negative breast cancer (TNBC)
• Study the clinical and safety data on the emerging therapies and treatment strategies for TNBC
• Define the role of the multidisciplinary oncology team in the management of TNBC therapy and coordination of care for patients

 Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity numbers 0290-0000-21-188-H01-P and 0290-0000-21-189-H01-T. The activity is available for CE credit through May 12, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Danielle Roman, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms